ReviewHematology/oncology clinics of North America2015
Paroxysmal nocturnal hemoglobinuria: a complement-mediated hemolytic anemia.
Review in Hematology/oncology clinics of North America, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 54 citations in OpenAlex.
- CD55 organizes lipid raft-LCK signaling to potentiate NK-cell antitumor immunity.Cell research · 2026Article
- Paroxysmal Nocturnal Hemoglobinuria as a Rare Cause of Chronic Asymptomatic Hemolysis: A Case Report.Cureus · 2026Article
- Real life use of ravulizumab in Italian patients with paroxysmal nocturnal hemoglobinuria: evidence from the REACTION observational study.Annals of hematology · 2026Observational
- Eculizumab and ravulizumab clinical trial and real-world pharmacovigilance of meningococcal infections across indications.PloS one · 2025Article
- Article
- Mathematical Modeling of Complement Pathway Dynamics for Target Validation and Selection of Drug Modalities for Complement Therapies.Frontiers in pharmacology · 2022Article
- A Review of Neutrophil Extracellular Traps (NETs) in Disease: Potential Anti-NETs Therapeutics.Clinical reviews in allergy & immunology · 2021Review
- MRI as a Aiagnostic Tool for Paroxysmal Nocturnal Hemoglobinuria: A Case Report.Sisli Etfal Hastanesi tip bulteni · 2021Article
- Article
- Laboratory studies for paroxysmal nocturnal hemoglobinuria, with emphasis on flow cytometry.Practical laboratory medicine · 2020Review
- Linking Complement C3 and B Cells in Nasal Polyposis.Journal of immunology research · 2020Article
- The Role of Complement in Transfusion-Related Acute Lung Injury.Transfusion medicine reviews · 2019Review
- Absence of complement component 3 does not prevent classical pathway-mediated hemolysis.Blood advances · 2019Article
- Novel insights into the treatment of complement-mediated hemolytic anemias.Therapeutic advances in hematology · 2019Review
- Red Blood Cell Homeostasis and Altered Vesicle Formation in Patients With Paroxysmal Nocturnal Hemoglobinuria.Frontiers in physiology · 2019Article
- The effect of splenectomy on complement regulatory proteins in erythrocytes in β-thalassemia major.Archives of medical science : AMS · 2019Article
- Eculizumab Bridging before Bone Marrow Transplant for Marrow Failure Disorders Is Safe and Does Not Limit Engraftment.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2018Article
- Identification of complement inhibitory activities of two chemotherapeutic agents using a high-throughput cell imaging-based screening assay.Molecular immunology · 2018Article
- Therapeutic challenges in pregnant women with paroxysmal nocturnal hemoglobinuria: A case report.Medicine · 2018Article
- Successful reduced-intensity conditioning hematopoietic stem cell transplantation for paroxysmal nocturnal hemoglobinuria with aplastic anemia in two children.Pediatric blood & cancer · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Paroxysmal nocturnal hemoglobinuria is manifests with a chronic hemolytic anemia from uncontrolled complement activation, a propensity for thrombosis and marrow failure. The hemolysis is largely mediated by the alternative pathway of complement. Clinical manifestations result from the lack of specific cell surface proteins, CD55 and CD59, on PNH cells. Complement inhibition by eculizumab leads to dramatic clinical improvement. While this therapeutic approach is effective, there is residual complement activity resulting from specific clinical scenarios as well as from upstream complement components that can account for suboptimal responses in some patients. Complement inhibition strategies are an area of active research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.